|
Nov 4
|
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Compared to Estimates, Lantheus Holdings (LNTH) Q3 Earnings: A Look at Key Metrics
|
|
Nov 2
|
Lantheus Holdings Inc (LNTH) Reports 33.7% Increase in Q3 2023 Revenue and Doubled Net Income
|
|
Nov 2
|
Lantheus Reports Third Quarter 2023 Financial Results
|
|
Sep 12
|
Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock
|
|
Sep 8
|
Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know
|
|
Jun 21
|
Lantheus Holdings (LNTH) Dips More Than Broader Markets: What You Should Know
|
|
Apr 27
|
Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know
|
|
Apr 24
|
Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Apr 24
|
Lantheus Holdings (LNTH) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
Apr 24
|
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
|
|
Apr 24
|
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
|